Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (ACB) announced that its board unanimously recommends shareholders reject Curaleaf Holdings’ unsolicited hostile takeover bid. The board advises investors to take no action, not tender their shares, and withdraw any shares already tendered.
Aurora states that it is debt free with approximately $149 million in cash, while Curaleaf carries over $1 billion in debt, based on each company’s June 30, 2026 financial statements. The company argues that the offer undervalues Aurora, does not provide an adequate change‑of‑control premium, and would give Curaleaf control over a portion of Aurora’s cash upon closing.
Aurora indicates that, based on the proposed exchange ratio, its shareholders would own about 7.7% of the combined company but hold only about 3.2% of the votes. The board reiterates confidence in Aurora’s standalone plan as a focused global medical cannabis business, highlighting its EU‑GMP manufacturing network, international footprint, and strong balance sheet.
Curaleaf (OTCQX: CURLF, TSX: CURA) issued a detailed response to recent public statements by Aurora Cannabis (TSX: ACB, NASDAQ: ACB) regarding Curaleaf's outstanding offer for Aurora. Curaleaf reiterates that it is offering Aurora shareholders a premium-valued transaction and the chance to participate in what it describes as a larger, stronger global cannabis platform, and says it remains willing to meet at any time to discuss terms.
According to Curaleaf, its proposal is based on Aurora’s latest published figures as of August 5, 2026, and it disputes Aurora’s description of the parties’ prior engagement. Curaleaf highlights, using figures it attributes to Aurora’s own disclosures, multi-year transformation costs exceeding C$400 million, a roughly 35% ACB share-price decline over the year to August 10, 2026 versus a 56% gain in Curaleaf’s shares, a June quarter adjusted EBITDA 63% lower than the March quarter (with C$5.1 million in add-backs), negative C$4.4 million cash flow from operations, and cultivation yields of 114 grams per plant versus more than double that level at Curaleaf. Curaleaf also notes that Aurora’s fiscal 2027 guidance points to lower revenue versus fiscal 2026, margin compression from about 64% to the mid‑to‑high‑50% range, and lower adjusted EBITDA, and states that Aurora’s share price rose materially after the offer announcement and has traded near the implied offer value, which Curaleaf views as support for the strategic rationale.
Aurora Cannabis (TSX/NASDAQ: ACB) responded to Curaleaf Holdings’ unsolicited hostile takeover bid, noting that a Special Committee of independent directors and the Board are reviewing the offer with financial and legal advisors. Shareholders are advised to take no action until a formal recommendation is issued; the offer remains open for at least 105 days from launch.
Aurora highlights its international medical cannabis strategy, reporting 17% year-over-year international net revenue growth in fiscal Q1 2027 and record global medical cannabis revenue and adjusted EBITDA in FY2026. The company reports three consecutive years of positive adjusted EBITDA, continued growth in Germany, leadership in Poland, and expanding presence in the UK through the acquisition of Internode Pharma and HAP Pharma. Aurora adds that EU-GMP production capacity has increased by more than 40% over five years, supporting global medical cannabis demand.
Aurora Cannabis (NASDAQ: ACB) announced the acquisition of Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy in Birmingham, UK. The deal gives Aurora direct ownership of a licensed import and distribution facility and a virtual pharmacy, extending its control from cultivation through to patient delivery in the UK medical cannabis market.
Aurora completed the transaction through a wholly owned subsidiary, indirectly buying 100% of both companies’ shares and paying selling shareholders GBP 2.1 million in cash, contingent on certain post-closing conditions. The company expects the acquisition to be accretive to future adjusted EBITDA through operational efficiencies, reduced reliance on third-party distributors and anticipated market share gains in the rapidly growing UK medical cannabis market.
Aurora Cannabis (TSX/NASDAQ: ACB) confirmed that Curaleaf Holdings has formally commenced an unsolicited take-over bid for all Aurora common shares. The Offer provides implied consideration of US$4.00 per share, made up of 0.3463 Curaleaf subordinate voting share plus US$0.75 in cash per Aurora share, and is subject to a value cap of US$5.00 per share, which Aurora notes is below the trading price reached on December 18, 2025.
The Offer must remain open for at least 105 days, giving Aurora shareholders until at least December 1, 2026 to respond. Aurora’s board has formed a special committee of independent directors to review the bid with external legal, financial, and advisory firms. Aurora is urging shareholders to take no action until the board issues a formal recommendation via a Directors’ Circular within 15 days of the bid.
Aurora Cannabis (NASDAQ: ACB; TSX: ACB) responded to Curaleaf Holdings’ stated intention to launch an unsolicited take-over bid for all Aurora common shares. The non-binding Proposal implies US$4.00 per Aurora share, composed of 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, and includes a cap of US$5.00 per share. Aurora confirms prior approach letters from Curaleaf and notes the bid was not solicited. The Board will form a special committee of independent directors to review the Proposal alongside other strategic alternatives, and no decision has been made. Aurora continues normal operations and advises shareholders that no action is required at this time.
Curaleaf (TSX:CURA, OTCQX:CURLF) announced its intention to launch a take‑over bid for all common shares of Aurora Cannabis (NASDAQ:ACB, TSX:ACB). The proposed consideration totals an implied US$4.00 per Aurora share, comprising 0.3463 Curaleaf subordinate voting share plus US$0.75 in cash.
According to Curaleaf, this reflects a 45% premium to Aurora’s 30‑day VWAP, or 110% excluding Aurora’s cash. If Curaleaf’s share price rises substantially before take‑up, total consideration per Aurora share would be capped at US$5.00, based on a 20‑day VWAP, which Curaleaf says would represent premiums of 82% and 197%, respectively.
Curaleaf has not yet formally commenced the bid and states there is no assurance the Offer will be made. The company highlights potential annual cost synergies of at least US$40 million, last‑twelve‑months pro forma revenue of over US$1.5 billion and nearly US$350 million in Adjusted EBITDA, and a pro forma market capitalization approaching US$3.0 billion for the combined entity. The Offer would not be subject to financing or due diligence conditions but remains contingent on multiple factors, including Curaleaf’s decision to proceed and potential defensive measures or alternative structures.
Aurora Cannabis (NASDAQ: ACB; TSX: ACB) reported voting results from its 2026 Annual General Meeting held virtually on August 7, 2026. Shareholders representing 16,639,306 common shares, or 26.86% of shares outstanding, were present or represented by proxy.
All five board nominees—Miguel Martin, Michael Singer, Chitwant Kohli, Norma Beauchamp and Rajesh Uttamchandani—received between roughly 85% and 87% of votes cast in favour. Shareholders also approved the reappointment of Ernst & Young LLP as auditors for the coming year and passed the advisory say‑on‑pay resolution with 82.97% of votes FOR.
Aurora Cannabis (NASDAQ | TSX: ACB) reported fiscal Q1 2027 net revenue of $67.6 million, down 9% year over year, with medical cannabis contributing $64.0 million. International medical cannabis net revenue rose 17% to $43.3 million, while Canadian medical cannabis fell to $20.7 million, mainly due to lower federal reimbursement rates.
Adjusted gross margin before fair value adjustments was 58% versus 64% a year ago. Net loss from continuing operations narrowed to $4.0 million from $10.2 million, but adjusted EBITDA declined to $3.4 million from $10.8 million and free cash flow swung to an outflow of $5.8 million. Aurora ended the quarter with $149.1 million in cash, cash equivalents and short-term investments and no debt. The Company closed the acquisition of Safari Flower Company, adding a 59,000 sq. ft. EU-GMP indoor facility, which later received a three-year EU-GMP certification, and reiterated its strategy to focus on global medical cannabis, expecting sequential increases in revenue and adjusted EBITDA in fiscal Q2.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) announced that independent proxy advisory firm Institutional Shareholder Services (ISS) has recommended that shareholders vote FOR all resolutions in advance of the company’s 2026 Annual General Meeting of Shareholders.
The virtual AGM will be held on Friday, August 7, 2026, at 1:00 p.m. Eastern / 11:00 a.m. Mountain via webcast at meetnow.global/MPUKQY6. Shareholders will vote to fix the board size at five directors, elect directors, appoint the auditor, and consider a non-binding say-on-pay resolution. According to Aurora, the board unanimously recommends voting FOR all resolutions, and the voting deadline is 1:00 p.m. Eastern on Wednesday, August 5, 2026.